insitro and Bristol Myers Squibb Collaboration Expanded with Nomination of New Targets

NodeGuardian

2026-03-25 06:02:36

Abstract generation in progress

insitro and Bristol Myers Squibb have expanded their collaboration to include two new therapeutic targets, ALS-2 and ALS-3, for treating amyotrophic lateral sclerosis (ALS). These targets were identified using insitro’s AI-driven Virtual Human™ platform, joining the previously nominated target, ALS-1. The partnership aims to develop disease-modifying interventions by leveraging multiple therapeutic modalities, including insitro’s oligonucleotide program for ALS-1 and a small molecule program for BMS, with insitro receiving a $10 million milestone payment for the new target nominations.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.